neurology

News

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

News

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.

News

NewAmsterdam has said that an oral drug it is developing to lower cholesterol has shown early efficacy as a preventive therapy for Alzheimer's.

News

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience.

News

Alzheon has been left sifting through data from a failed Alzheimer's trial for crumbs of evidence that its oral therapy may have some efficacy.

News

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.